Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Acapatamab

Acapatamab will be administered as an intravenous (IV) infusion.

DRUG

Enzalutamide

Enzalutamide will be administered orally.

DRUG

Abiraterone

Abiraterone will be administered orally.

DRUG

AMG 404

AMG 404 will be administered as an intravenous (IV) infusion.

Trial Locations (14)

2010

St Vincents Hospital Sydney, Darlinghurst

2100

Rigshospitalet, København Ø

31008

Clinica Universidad de Navarra, Pamplona

35294

University of Alabama at Birmingham, Birmingham

40207

Norton Cancer Institute, Louisville

60637

University of Chicago, Chicago

75185

Akademiska sjukhuset, Uppsala

75390

University of Texas Southwestern Medical Center, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

92868

University of California at Irvine Medical Center, Orange

94158

University of California San Francisco Mission Bay Campus, San Francisco

221 85

Skanes universitetssjukhus, Lund

171 76

Karolinska Universitetssjukhuset Solna, Stockholm

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY